

Special Issue

Nanotheranostics and Artificial Intelligence to Combat the COVID-19 Pandemic

Message from the Guest Editors

Taking challenges, state-of-the-art technology, and demand into consideration, this Special Issue welcomes technical notes, reviews, or research articles focused on exploring AI, nanotheranostics, or both, to combat SARS-CoV-2 and manage the COVID-19 pandemic. We particularly welcome contributions that include, but are not limited to, the following topics and their application for addressing COVID-19's challenges:

- Nanosystems;
- Theragnostic approaches;
- Nanomedicine;
- Nano-assisted multi-functional approaches;
- Artificial Intelligence;
- Therapy development.

Guest Editors

Dr. Ajeet Kaushik

Department of Natural Sciences, Division of Sciences, Arts & Mathematics (SAM), Florida Polytechnic University, Lakeland, FL 33805-8531, USA

Dr. Hardik A. Gohel

Assistant Professor & Associate Director of Computer Science, Founder & Director of Applied AI Research Laboratory, University of Houston at Victoria, 3007 N Ben Wilson St, Victoria, TX 77901, USA

Deadline for manuscript submissions

closed (31 December 2021)



Journal of
Nanotheranostics

an Open Access Journal
by MDPI



mdpi.com/si/57115

Journal of Nanotheranostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
nanotheranostics@mdpi.com

mdpi.com/journal/

[jnt](#)





Journal of Nanotheranostics

an Open Access Journal
by MDPI



mdpi.com/journal/

[jnt](https://jnt.mdpi.com/)



About the Journal

Message from the Editor-in-Chief

The *Journal of Nanotheranostics (JNT)* is an open-access, peer-reviewed international journal by MDPI providing a critical forum for the dissemination of fundamental, translational, and clinical developments in nanotheranostics. The journal considers outstanding papers on all aspects of nanotheranostics, including targeted therapies, device engineering, computational simulations, molecular imaging, and clinical reports. Manufacturing, ethical, and regulatory issues in nanotheranostics are also considered. Furthermore, *JNT* welcomes papers reporting negative results, as these contribute to advancing the field. The journal also publishes Special Issues on emerging topics that foster new ideas and research directions.

On behalf of the Editorial Board, I warmly invite you to submit your latest research and proposals for Special Issues to *JNT*, and I look forward to receiving your contributions. Together, we will build an outstanding journal.

Editor-in-Chief

Prof. Dr. Seyed Moein Moghimi

1. Pharmaceutics and Nanomedicine, School of Pharmacy, Newcastle University, Newcastle upon Tyne NE1 7RU, UK
2. Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE1 7RU, UK
3. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Denver, Denver, CO 80204, USA

Author Benefits

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 24.1 days after submission; acceptance to publication is undertaken in 4.2 days (median values for papers published in this journal in the second half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer-review and reviewer names published annually in the journal.